Aart Beeker

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 562 citations

Surgical Oncology, Chemotherapy Versus Chemoradiotherapy, Gastrointestinal Oncology +8

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Sil Kordes, Michaël Pollak, Aeilko H. Zwinderman et al. · The Lancet Oncology · 2015 · 372 citations

Placebo-controlled Phase 2, Oncology, Pancreatic Cancer +8

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina et al. · The Lancet Oncology · 2019 · 229 citations

Neuro-oncology, Lymphoid Neoplasia, Medicine +9

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 157 citations

Medicine, Clinical Trials, Gynecology +10

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans et al. · British Journal of Haematology · 2011 · 106 citations · Full text